ERBB2 and breast cancer: Previous studies have demonstrated the strong predictive effect of peritumoral radiomics features in the diagnosis of breast cancer, lymph node metastasis status, molecular typing, neoadjuvant chemotherapy efficacy, HER2 expression status, KI-67 expression level, lymphovascular invasion and programmed cell death ligand 1 (PD-L1) expression status (28–35).